Unlabeled aspirin as an activatable theranostic MRI agent for breast cancer is a research paper published in Theranostics (2022). On theSindex it has a DataRank of 0. It has been cited 6 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
NCI NIH HHS
Grant: R01 CA264901
NCI NIH HHS
Grant: R01 CA213492
NCI NIH HHS
Grant: R01 CA213428
NIBIB NIH HHS
Grant: P41 EB024495
National Institutes of Health
Grant: 5R01DK121847-03
Developing MRI contrast agents to detect progression in renal disease as a consequence of acidema
National Institutes of Health
Grant: 5R01CA213492-05
Hypoxia-derived molecular MSI signatures to predict breast cancer outcome
National Institutes of Health
Grant: 1R01CA213428-01A1
Molecular studies of the MR-detectable oncometabolite glycerophosphocholine
National Institutes of Health
Grant: 5P41EB024495-02
Resource for Molecular Imaging Agents in Precision Medicine
FWCI
0.34
Citation Percentile
0.4%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals